Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Simvastatin and fenofibrate are both commonly used lipid‐regulating agents with distinct mechanisms of action, and their coadministration may be an attractive treatment for some patients with dyslipidemia. A 2‐period, randomized, open‐label, crossover study was conducted in 12 subjects to determine if fenofibrate and simvastatin are subject to a clinically relevant pharmacokinetic interaction at steady state. In treatment A, subjects received an 80‐mg simvastatin tablet in the morning for 7 days. In treatment B, subjects received a 160‐mg micronized fenofibrate capsule in the morning for 7 days, followed by a 160‐mg micronized fenofibrate capsule dosed together with an 80‐mg simvastatin tablet on days 8 to 14. Because food increases the bioavailability of fenofibrate, each dose was administered with food to maximize the exposure of fenofibric acid. The steady‐state pharmacokinetics (AUC 0–24h, C max, and t max) of active and total HMG‐CoA reductase inhibitors, simvastatin acid, and simvastatin were determined following simvastatin administration with and without fenofibrate. Also, fenofibric acid steady‐state pharmacokinetics were evaluated with and without simvastatin. The geometric mean ratios (GMRs) for AUC 0–24h (80 mg simvastatin [SV] + 160 mg fenofibrate)/(80 mg simvastatin alone) and 90% confidence intervals (CIs) were 0.88 (0.80, 0.95) and 0.92 (0.82, 1.03) for active and total HMG‐CoA reductase inhibitors. The GMRs and 90% CIs for fenofibric acid (80 mg SV + 160 mg fenofibrate/160 mg fenofibrate alone) AUC 0–24h and C max were 0.95 (0.88, 1.04) and 0.89 (0.77, 1.02), respectively. Because both the active inhibitor and fenofibric acid AUC GMR 90% confidence intervals fell within the prespecified bounds of (0.70, 1.43), no clinically significant pharmacokinetic drug interaction between fenofibrate and simvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a finding that was compatible with evidence that fenofibrate, in contrast to gemfibrozil, does not increase plasma concentrations of statins.28”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [28]
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“Thus, simvastatin acid and other active metabolites effectively inhibit the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol.(7)”
BackgroundCerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626 · cited 1×
“Furthermore, cerivastatin was recently withdrawn from the market after reports of an increased incidence of deaths due to rhabdomyolysis (a severe muscle adverse reaction), especially when coadministered with gemfibrozil.(22) Coadministration of gemfibrozil has been shown to increase the plasma AUC of cerivastatin 5-…”
BackgroundGemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336 · cited 1×
“All incubations were performed in triplicate, as described previously.(21) In brief, simvastatin acid glucuronidation was assayed in 0.”
MethodEffects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 325 · cited 4×
“In vitro experiments suggest that the mechanism of the interactions between gemfibrozil and some statins involves inhibition of the statin hydroxy acid glucuronidation by gemfibrozil.(23,24) However, some reports suggest that gemfibrozil may also affect statins through other mechanisms.”
BackgroundMethodResultSelf-citationMechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 287 · cited 4×
“In vitro experiments suggest that the mechanism of the interactions between gemfibrozil and some statins involves inhibition of the statin hydroxy acid glucuronidation by gemfibrozil.(23,24) However, some reports suggest that gemfibrozil may also affect statins through other mechanisms.”
BackgroundMethodResultSelf-citationPedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264 · cited 4×
“In a recent publication, it was reported that simvastatin acid AUC was increased 185% and simvastatin AUC was increased 35% when simvastatin was coadministered with gemfibrozil.(13) In vitro experiments suggest that the mechanism of the interactions between gemfibrozil and some statins involves inhibition of the stati…”
BackgroundInfluentialKyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189 · cited 1×
“This interaction may be due, in part, to inhibition of organic anion transporting polypeptide (OATP) or some other transporter of pravastatin by gemfibrozil.(19) Although gemfibrozil exhibits pharmacokinetic interactions with several statins, this may not be indicative of pharmacokinetic drug interactions between feno…”
BackgroundClinical Pharmacokinetics and Practical Applications of Simvastatin
Mauro, V. F. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00002 · Cited by 188 · cited 1×
“S (ZOCOR) is a highly effective agent for reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) and increasing highdensity lipoprotein cholesterol (HDL-C) at doses up to 80 mg per day.(1) It also has been shown to reduce cardiovascular mortality and morbidity in a wide range of high risk patients.”
BackgroundRifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.
Vickers, S., Duncan, C. A., Vyas, K. P., Kari, P. H., Arison, B., Prakash, S. R., Ramjit, H. G., Pitzenberger, S. M., Stokker, G., & Duggan, D. E. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08543-5 · Cited by 154 · cited 1×
“Simvastatin acid and other simvastatin-derived active metabolites are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.(6) Thus, simvastatin acid and other active metabolites effectively inhibit the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis…”
BackgroundAdkins, J. C., & Faulds, D. M. (1997) · Drugs · doi:10.2165/00003495-199754040-00007 · Cited by 151
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
Gruer, P. J. K., Vega, J. M., Mercuri, M. F., Dobrinska, M. R., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00442-7 · Cited by 130
Self-citationKeating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 128
Martin, P. D., Dane, A. L., Schneck, D. W., & Warwick, M. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80089-9 · Cited by 103
Pan, W., Gustavson, L. E., Achari, R., Rieser, M. J., Ye, X., Gutterman, C., & Wallin, B. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008874 · Cited by 91
Zhao, J. J., Xie, I. H., Yang, A. Y., Roadcap, B. A., & Rogers, J. D. (2000) · Journal of Mass Spectrometry · doi:10.1002/1096-9888(200009)35:9<1133::aid-jms42>3.0.co;2-x · Cited by 82 · cited 1×
“multaneously according to a published method using a liquid chromatography/tandem mass spectrometry method.(25,26) The simvastatin acid and simvastatin assays both had a linear calibration range of 0.”
MethodMicronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent
Guay, D. R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18432 · Cited by 69
Cheng, H., Rogers, J. D., Sweany, A. E., Dobrinska, M. R., Stein, E. A., Tate, A. C., Amin, R. D., & Quan, H. (1992) · Pharmaceutical Research · doi:10.1023/a:1015828811865 · Cited by 57
Zhao, J. J., Yang, A. Y., & Rogers, J. D. (2002) · Journal of Mass Spectrometry · doi:10.1002/jms.299 · Cited by 56 · cited 2×
“The acetonitrile extracts were evaporated to dryness and reconstituted for analysis by HPLC with UV detection.(26)”
MethodSelf-citationInteractions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects
Prueksaritanont, T., Vega, J. M., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., Amin, R. D., Liu, L., Roadcap, B. A., Dilzer, S., et al. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010311 · Cited by 55
Self-citationThe Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention
Farmer, J. A., & Gotto, A. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00503-4 · Cited by 48
Streel, B., Hubert, P., & Ceccato, A. (2000) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00195-x · Cited by 47 · cited 1×
“Unchanged fenofibrate has been reported to be undetectable in plasma samples following an oral dose.(18) The mechanism of action of fenofibrate and other fibrates is distinct from that of simvastatin and other statins.”
BackgroundLiu, L., Zhang, R., Zhao, J. J., Rogers, J., Hsieh, J. Y. ‐., Fang, W. H., Matuszewski, B. K., & Dobrinska, M. R. (2003) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(03)00023-2 · Cited by 19 · cited 1×
“The HMG-CoA reductase inhibitory activity of the plasma samples was measured according to an enzymatic activity assay.(9) All plasma inhibitor concentrations are expressed in simvastatin acid equivalents.”
MethodSelf-citationRobotic inhibition assay for determination of HMG‐CoA reductase inhibitors in human plasma
Fang, W., Liu, L., Hsieh, J. Y. ‐., Zhao, J. J., Matuszewski, B. K., Rogers, J., & Dobrinska, M. R. (2002) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.10046 · Cited by 10
Self-citation
Research works printed but not linked: 4
- Scandinavian Simvastatin Survival Group, 1994, Randomised trial of cholesterol lowering in 4444 patients with coronoary heart disease the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
- 10.1001/archinte.1996.00440170097011 · DOI · Paper page
- 10.1016/s0009-9236(03)00052-3 · DOI · Paper page
- 2003, Crestor® product information
Cited by
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Metadata
- Authors
- Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., Hartford, A., Vega, J. M., & Paolini, J. F.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Bergman, Arthur J.
- ORCID
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 44
- Issue
- 9
- Pages
- 1054-1062
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2053536280
- Cited by
- 97
- References
- 27
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 1 · 2021: 1 · 2019: 3 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 8
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, fenofibrate, drug-drug interactions, pharmacokinetic interactions, statins, fenofibric acid, lipid-lowering therapy, dyslipidemia, crossover design, steady-state pharmacokinetics, 90% confidence interval
- MeSH terms
- Adolescent, Adult, Hypolipidemic Agents, Biotransformation, Blood Cell Count, Drug Interactions, Electrocardiography, Female, Half-Life, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Microsomes, Liver, Middle Aged, Fenofibrate, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve, Simvastatin, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.